An observational study in Metabolic Syndrome and Diabetes, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by National Taiwan University Hospital · Observational
Among 16 studies in Metabolic Syndrome by National Taiwan University Hospital — 5 open to participants now, 5 under way, none of them phase 3. Metabolic Syndrome · National Taiwan University Hospital.
Among the 16 studies in Metabolic Syndrome by National Taiwan University Hospital, this one is one of 3 that started in 2025, is one of 10 observational ones, and was the 16th registered.
2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 197 across 496 observational studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →5 of the 16 studies in Metabolic Syndrome by National Taiwan University Hospital are open now, in 1 country. Each count lists the studies.
Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 136 (59%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →16 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
Median enrollment 120 across the 5 interventional studies, 289 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
2 of the studies in Metabolic Syndrome by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239167National Taiwan University HospitalA Prospective Cohort Study on Patient With Obesity Undergoing Weight Change | 2027-04-08 |
| NCT05956379National Taiwan University HospitalChronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention. | 2027-07-31 |
Among the 16 studies in Metabolic Syndrome by National Taiwan University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This study aims to establish a cohort of individuals with metabolic syndrome and prediabetes to enable long-term follow-up of risk factors, disease progression, and the development of obesity-related complications. The study will also monitor changes in nutritional status and physical function over time, in order to identify key prognostic determinants influencing clinical outcomes.
Metabolic syndrome and prediabetes are chronic multisystem disorders, and poor long-term control is closely associated with the development of various complications. Moreover, malnutrition and functional decline are common comorbid conditions that further impair quality of life and impose a substantial burden on healthcare resources.
Metabolic syndrome has been recognized as a significant contributor to the development of major chronic diseases, including cerebrovascular disorders, cardiovascular disease, diabetes mellitus, and hypertension. Compared with the general population, individuals with metabolic syndrome exhibit an approximately sixfold increased risk of diabetes, fourfold risk of hypertension, threefold risk of dyslipidemia, and twofold risk of stroke and coronary heart disease.
The condition is strongly influenced by dietary and lifestyle factors. Its core pathophysiological features are insulin resistance and central obesity, and there is a high degree of comorbidity between metabolic syndrome and prediabetes.
The establishment of a comprehensive cohort and database for individuals with metabolic syndrome and prediabetes will facilitate the systematic collection of metabolic profiles and disease-related biomarkers. This will enable longitudinal analyses of systemic and organ-specific complications, their incidence, and predictive determinants, thereby strengthening disease risk stratification and early identification.
This study aims to collect routine clinical, physiological, and nutritional data at regular intervals to examine associations among lifestyle behaviors, metabolic factors, physiological indicators, and the development of complications. Furthermore, it seeks to evaluate nutritional and functional status, identify potential prognostic biomarkers, and provide a foundation for individualized therapeutic approaches and integrated healthcare models.
articipants eligible for inclusion are adults aged 18 years or older who have been clinically diagnosed with either metabolic syndrome or prediabetes. Metabolic syndrome is defined by the presence of at least three of the following five criteria: (A) waist circumference ≥ 90 cm in men or ≥ 80 cm in women, or a body mass index (BMI) ≥ 27 kg/m²; (B) fasting plasma glucose ≥ 100 mg/dL; (C) systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg; (D) triglycerides ≥ 150 mg/dL; and (E) high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dL in men or \< 50 mg/dL in women.
Participants meeting the definition of prediabetes, defined as glycated hemoglobin (HbA1c) levels between 5.7% and 6.4%, will also be eligible. All participants must be willing to join the study, provide written informed consent, and be able to complete basic physical examinations and assessment procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals clinically diagnosed by a physician as having metabolic syndrome (meeting at least three of the following five criteria) or prediabetes:
(A) Waist circumference: ≥ 90 cm in men or ≥ 80 cm in women, or (BMI) ≥ 27 kg/m².
(B) Fasting plasma glucose (AC): ≥ 100 mg/dL. (C) Blood pressure: Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg.
(D) Triglycerides (TG): ≥ 150 mg/dL. (E) High-density lipoprotein cholesterol (HDL-C): \< 40 mg/dL in men or \< 50 mg/dL in women.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medical record system and on-site inspection data collection
Time frame: Everytime after physician's appointment(Usually 3 months).
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2028, 34 months after the start.
Of 149 non-industry observational studies under Metabolic Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 106. This study's planned 34 months is below that.
Counting every sponsor, half of 160 studies reached it within 42 months; a quarter within 18 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →